GeneMatrix Inc Cash Flow-to-Debt Ratio
GeneMatrix Inc cash flow-to-debt ratio. GeneMatrix Inc (109820) has a Cash Flow-to-Debt Ratio of 0.05x as of September 2025, meaning its operating cash flow of ₩500.19 Million could theoretically repay 0% of its total liabilities (₩9.72 Billion) in one year. Check 109820 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of GeneMatrix Inc (2014–2024)
Cash flow-to-debt ratio of GeneMatrix Inc from 2014 to 2024. Historical debt coverage capacity for GeneMatrix Inc across 11 annual periods. Check 109820 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
GeneMatrix Inc Cash Flow-to-Debt Ratio by Year (2014–2024)
GeneMatrix Inc cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for GeneMatrix Inc. For the full cash flow conversion analysis, see 109820 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.02x | ₩-200.12 Million | ₩9.23 Billion | ▲ +92.4% |
| 2023 | -0.29x | ₩-2.35 Billion | ₩8.21 Billion | ▼ -115.6% |
| 2022 | -0.13x | ₩-1.02 Billion | ₩7.72 Billion | ▼ -128.4% |
| 2021 | 0.47x | ₩3.37 Billion | ₩7.21 Billion | ▼ -50.5% |
| 2020 | 0.94x | ₩4.51 Billion | ₩4.78 Billion | ▲ +647.1% |
| 2019 | -0.17x | ₩-2.28 Billion | ₩13.21 Billion | ▼ -30.3% |
| 2018 | -0.13x | ₩-2.74 Billion | ₩20.68 Billion | ▲ +50.1% |
| 2017 | -0.27x | ₩-1.77 Billion | ₩6.68 Billion | ▼ -387.1% |
| 2016 | -0.05x | ₩-373.25 Million | ₩6.85 Billion | ▲ +1.1% |
| 2015 | -0.06x | ₩-591.96 Million | ₩10.74 Billion | ▲ +79.3% |
| 2014 | -0.27x | ₩-1.38 Billion | ₩5.16 Billion | — |